NAUT vs. LAB, SENS, CTKB, AEHR, QSI, QTRX, FEIM, MASS, RPID, and SEER
Should you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Standard BioTools (LAB), Senseonics (SENS), Cytek Biosciences (CTKB), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), Frequency Electronics (FEIM), 908 Devices (MASS), Rapid Micro Biosystems (RPID), and Seer (SEER). These companies are all part of the "measuring and control equipment" industry.
Nautilus Biotechnology vs.
Nautilus Biotechnology (NASDAQ:NAUT) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.
Nautilus Biotechnology presently has a consensus price target of $2.42, suggesting a potential upside of 208.01%. Standard BioTools has a consensus price target of $2.50, suggesting a potential upside of 140.38%. Given Nautilus Biotechnology's higher probable upside, analysts clearly believe Nautilus Biotechnology is more favorable than Standard BioTools.
Standard BioTools received 1 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 83.33% of users gave Standard BioTools an outperform vote while only 18.18% of users gave Nautilus Biotechnology an outperform vote.
Nautilus Biotechnology has a net margin of 0.00% compared to Standard BioTools' net margin of -79.92%. Standard BioTools' return on equity of -27.05% beat Nautilus Biotechnology's return on equity.
50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by insiders. Comparatively, 23.2% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Nautilus Biotechnology and Nautilus Biotechnology both had 1 articles in the media. Standard BioTools' average media sentiment score of 1.67 beat Nautilus Biotechnology's score of 0.80 indicating that Standard BioTools is being referred to more favorably in the news media.
Nautilus Biotechnology has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500.
Nautilus Biotechnology has higher earnings, but lower revenue than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Standard BioTools beats Nautilus Biotechnology on 10 of the 15 factors compared between the two stocks.
Get Nautilus Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nautilus Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:NAUT) was last updated on 5/22/2025 by MarketBeat.com Staff
